Medical/Pharmaceuticals
I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...
2021-08-30 20:00
1525
Zamst Announces Sponsorship with Wilfredo León Venero, a Polish Pro Volleyball Player
TOKYO, Aug. 30, 2021 /PRNewswire/ -- Nippon Sigmax Co., Ltd., a company owning "Zamst," a brand of athletic braces and care products headquartered inTokyo, Japan, announced a global sponsorship agreement with Wilfredo León Venero, men's professional volleyball player playing for the SIR Safety Pe...
2021-08-30 14:00
2106
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
STATE COLLEGE, Pa., Aug. 30, 2021 /PRNewswire/ -- NeuExcell Therapeutics ( www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors Yua...
2021-08-30 13:00
1536
Alphamab Oncology Reports 2021 Interim Results and Business Highlights
SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2021 ...
2021-08-30 10:51
3581
GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science
SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...
2021-08-30 10:00
1204
Kenya Grants Emergency Use Authorization for the INDICAID(TM) COVID-19 Rapid Antigen Test
HONG KONG, Aug. 30, 2021 /PRNewswire/ -- PHASE Scientific announces that its INDICAID™ COVID-19 Rapid Antigen Test (INDICAID™) has received Emergency Use Authorization from the Ministry of Health (MOH) of the Republic ofKenya on 17 August 2021. The authorization enables the test to be used in Ken...
2021-08-30 09:00
3507
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021
SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2021-08-30 08:00
3206
Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that the former President and Head of Research & Clinical Development, Dr.Henri Nico Doods, will serve as the company's Chief Executive Officer. Dr...
2021-08-30 08:00
4192
InnoCare Releases 2021 Half Year Results and Business Highlights
BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended onJune 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On the fo...
2021-08-29 19:49
4412
IONOVA Life Science Announces New Financing Round of USD $100 Million
SHENZHEN, China, Aug. 27, 2021 /PRNewswire/ -- On August 27, 2021, Shenzhen IONOVA Life Science Co., Ltd. ("IONOVA" or "the company"), a clinical-stage biotechnology company located in theGuangdong-Hong Kong-Macao Greater Bay Area ofChina, announced completion of a new financing round of USD $100...
2021-08-27 22:00
2852
Bunshi Lab Starts Accepting Pre-orders for "Bunshi Mask" -- Best-selling Crowdfunded Face Mask in Japan -- through "Indiegogo" Crowdfunding Website
FUKUOKA, Japan, Aug. 27, 2021 /PRNewswire/ -- Bunshi Lab ("bunshi" meaning molecule in Japanese) has raised approximately180 million yen (*1) for the "Bunshi Mask" through "Makuake," a Japanese crowdfunding website. Now, Bunshi Lab is launching a much-awaited global sales campaign for the product...
2021-08-27 16:00
1148
Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer
SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) ofChina has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate...
2021-08-27 11:20
1415
MediCap Sdn Bhd Achieves Over 50% of the RM2,000,000 Equity Crowdfunding Goal to Expand 5-in-1 Health Hubs
PETALING JAYA, Malaysia, Aug. 27, 2021 /PRNewswire/ -- MediCap Sdn Bhd (MediCap) has amassed RM1,025,000 in equity crowdfunding, over 50% of the minimum goal ofRM2,000,000 through MyStartr, Malaysia's leading equity crowdfunding platform approved by the Malaysia Security Commission, in a bid to ...
2021-08-27 09:00
2821
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of$50 million, with Lilly Asia Ventures (LAV) as lead ...
2021-08-27 08:00
4075
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
SAN FRANCISCO and SUZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-08-27 08:00
4461
JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions
Population–based cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs. PLYMOUTH MEETING, Pa., Aug. 27, 2021 /PRNewswire/ -- Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer...
2021-08-27 03:30
1700
Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases
SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, and4B Technologies Co., Ltd. ("4B Technologies"), a leading end-to-end innovative biopharmaceutical company focusing on nervous system diseases, signed...
2021-08-27 03:22
28287
PharmaBlock Announces the Appointment of Dr. Xudong Wei as Senior Vice President to Lead and Enhance Small Molecule CDMO Services
NANJING, China, Aug. 26, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Xudong Wei as Senior Vice President and Head of CDMO Business to enhance s...
2021-08-26 23:00
3014
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...
2021-08-26 22:09
5338
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer
SHANGHAI, Aug. 26, 2021 /PRNewswire/ -- Everest Medicines
2021-08-26 21:40
4432
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 317 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 312 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 306 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 290 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
14378
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
9999
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9532
